ERBB2 and gastric adenocarcinoma: Although these analyses are limited by the small sample size of patients with available survival data, these data suggest that CCNE1 amplification may be associated with clinical outcomes in response to either HER2-targeted therapy or immunotherapy, specifically in patients with gastric adenocarcinoma.